FHL family members suppress vascular endothelial growth factor expression through blockade of dimerization of HIF1α and HIF1β

IUBMB Life

Volumn 64, Issue 11, 2012, Pages 921-930

  Lin, Jing ^a,b   Qin, Xi ^a   Zhu, Ziman ^b   Mu, Jinsong ^c   Zhu, Lingling ^d   Wu, Kuiwu ^d   Jiao, Huabo ^b   Xu, Xiaojie ^a   Ye, Qinong ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c 302 MILITARY HOSPITAL   (China)

^d Department of Pharmacology   (China)

Author keywords

four and a half LIM domain; hypoxia inducible factor 1; protein protein interaction; transcriptional activity; vascular endothelial growth factor

Indexed keywords

FOUR AND A HALF LIM DOMAIN PROTEIN 1; FOUR AND A HALF LIM DOMAIN PROTEIN 2; FOUR AND A HALF LIM DOMAIN PROTEIN 3; HELIX LOOP HELIX PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LIM PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION TERMINATION; TUMOR VASCULARIZATION;

ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIM DOMAIN PROTEINS; LIM-HOMEODOMAIN PROTEINS; LUCIFERASES; MUSCLE PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN MULTIMERIZATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867826626     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1089     Document Type: Article

References (37)

1. Bergers, G., and, Benjamin, L. E., (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410.
2. Cao, Y., and, Liu, Q., (2007) Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv. Cancer Res. 97, 203-224.
3. Majmundar, A. J., Wong, W. J., and, Simon, M. C., (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309.
4. Semenza, G. L., (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634.
5. Jokilehto, T., and, Jaakkola, P. M., (2010) The role of HIF prolyl hydroxylases in tumour growth. J. Cell Mol. Med. 14, 758-770.
6. Onnis, B., Rapisarda, A., and, Melillo, G., (2009) Development of HIF-1 inhibitors for cancer therapy. J. Cell Mol. Med. 13, 2780-2786.
7. Johannessen, M., MÃller, S., Hansen, T., Moens, U., and, Van Ghelue, M., (2006) The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol. Life Sci. 63, 268-284.
8. Ding, L., Niu, C., Zheng, Y., Xiong, Z., Liu, Y., et al. (2011) FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth. J. Cell Mol. Med. 15, 72-85.
9. Li, X., Jia, Z., Shen, Y., Ichikawa, H., Jarvik, J., et al. (2008) Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 99, 1326-1333.
10. Ding, L., Wang, Z., Yan, J., Yang, X., Liu, A., et al. (2009) Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β-like signaling pathway. J. Clin. Invest. 119, 349-361.
11. Sakashita, K., Mimori, K., Tanaka, F., Kamohara, Y., Inoue, H., et al. (2008) Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann. Surg. Oncol. 15, 2293-2300.
12. Niu, C., Liang, C., Guo, J., Cheng, L., Zhang, H., et al. (2012) Downregulation and growth inhibitory role of FHL1 in lung cancer. Int. J. Cancer. 130, 2549-2556.
13. Shen, Y., Jia, Z., Nagele, R. G., Ichikawa, H., and, Goldberg, G. S., (2006) SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res. 66, 1543-1552.
14. Scholl, F. A., McLoughlin, P., Ehler, E., de Giovanni, C., and, Schäfer, B. W., (2000) DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J. Cell Biol. 151, 495-506.
15. Gabriel, B., Mildenberger, S., Weisser, C. W., Metzger, E., Gitsch, G., et al. (2004) Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res. 24, 921-927.
16. Wang, J., Yang, Y., Xia, H. H., Gu, Q., Lin, M. C., et al. (2007) Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 132, 1066-1076.
17. Niu, C., Yan, Z., Cheng, L., Zhu, J., Zhang, H., et al. (2011) Downregulation and antiproliferative role of fhl3 in breast cancer. IUBMB Life 63, 764-771.
18. Xiong, Z. H., Ding, L. H., Yang, S. X., Sun, Q. H., Yang, X., et al. (2007) The cloning of the VEGF promoter reporter and the effect of estrogen receptor on the reporter activity. Lett. Biotech. 18, 915-917.
19. Ding, L., Yan, J., Zhu, J., Zhong, H., Lu, Q., et al. (2003) Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Res. 31, 5266-5274.
20. Cheng, L., Li, J., Han, Y., Lin, J., Niu, C., et al. (2012) PES1 promotes breast cancer by differentially regulating ERα and ERβ. J. Clin. Invest. 122, 2857-2870.
21. Kang, H. J., Kim, H. J., Rih, J. K., Mattson, T. L., Kim, K. W., et al. (2006) BRCA1 plays a role in the hypoxic response by regulating HIF-1α stability and by modulating vascular endothelial growth factor expression. J. Biol. Chem. 281, 13047-13056.
22. Hubbi, M. E., Gilkes, D. M., Baek, J. H., and, Semenza, G. L., (2012) Four-and-a-half LIM domain proteins inhibit transactivation by hypoxia-inducible factor 1. J. Biol. Chem. 287, 6139-6149.
23. Kleiber, K., Strebhardt, K., and, Martin, B. T., (2007) The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res. 27, 55-61.
24. Lin, J., Ding, L., Jin, R., Zhang, H., Cheng, L., et al. (2009) Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140 kDa (RIP140) interact and cooperate in estrogen signaling. Int. J. Biochem. Cell Biol. 41, 1613-1618.
25. Bai, S., Kitaura, H., Zhao, H., Chen, J., Müller, J. M., et al. (2005) FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J. Clin. Invest. 115, 2742-2751.
26. Purcell, N. H., Darwis, D., Bueno, O. F., Müller, J. M., Schüle, R., et al. (2004) Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol. Cell Biol. 24, 1081-1095.
27. McGrath, M. J., Cottle, D. L., Nguyen, M. A., Dyson, J. M., Coghill, I. D., et al. (2006) Four and a half LIM protein 1 binds myosin-binding protein C and regulates myosin filament formation and sarcomere assembly. J. Biol. Chem. 281, 7666-7683.
28. Paul, C., Lacroix, M., Iankova, I., Julien, E., Schäfer, B. W., et al. (2006) The LIM-only protein FHL2 is a negative regulator of E4F1. Oncogene 25, 5475-5484.
29. Foxler, D. E., Bridge, K. S., James, V., Webb, T. M., Mee, M., et al. (2012) The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat. Cell Biol. 14, 201-208.
30. Hao, N., Whitelaw, M. L., Shearwin, K. E., Dodd, I. B., and, Chapman-Smith, A., (2011) Identification of residues in the N-terminal PAS domains important for dimerization of Arnt and AhR. Nucleic Acids Res. 39, 3695-3709.
31. Kewley, R. J., Whitelaw, M. L., and, Chapman-Smith, A., (2004) The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int. J. Biochem. Cell Biol. 36, 189-204.
32. Yang, J., Zhang, L., Erbel, P. J., Gardner, K. H., Ding, K., et al. (2005) Functions of the Per/ARNT/Sim domains of the hypoxia-inducible factor. J. Biol. Chem. 280, 36047-36054.
33. Niu, G., and, Chen, X., (2010) Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr. Drug Targets 11, 1000-1017.
34. Ellis, L. M., and, Hicklin, D. J., (2008) VEGF-targeted therapy: mechanisms of antitumour activity. Nat. Rev. Cancer 8, 579-591.
35. Chen, H. X., and, Cleck, J. N., (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6, 465-477.
36. Duda, D. G., Batchelor, T. T., Willett, C. G., and, Jain, R. K., (2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol. Med. 13, 223-230.
37. Cardones, A. R., and, Banez, L. L., (2006) VEGF inhibitors in cancer therapy. Curr. Pharm. Des. 12, 387-394.